ATA900589A - Stereospezifisches verfahren fuer die herstellung von enantiomeren des 3-substituierten furo (3,4-c) pyridins, so erhaltene enantiomere oder mischungen davon sowie diese enthaltene therapeutische mittel - Google Patents

Stereospezifisches verfahren fuer die herstellung von enantiomeren des 3-substituierten furo (3,4-c) pyridins, so erhaltene enantiomere oder mischungen davon sowie diese enthaltene therapeutische mittel

Info

Publication number
ATA900589A
ATA900589A AT0900589A AT900589A ATA900589A AT A900589 A ATA900589 A AT A900589A AT 0900589 A AT0900589 A AT 0900589A AT 900589 A AT900589 A AT 900589A AT A900589 A ATA900589 A AT A900589A
Authority
AT
Austria
Prior art keywords
enantiomers
stereo
pyridine
mixtures
production
Prior art date
Application number
AT0900589A
Other languages
English (en)
Other versions
AT397093B (de
Inventor
Marc Bonato
Charles Eck
Original Assignee
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras filed Critical Scras
Publication of ATA900589A publication Critical patent/ATA900589A/de
Application granted granted Critical
Publication of AT397093B publication Critical patent/AT397093B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT0900589A 1988-04-06 1989-04-06 Stereospezifisches verfahren für die herstellung von enantiomeren des 3-substituierten furo (3,4-c) pyridins, so erhaltene enantiomere oder mischungen davon sowie diese enthaltene therapeutische mittel AT397093B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888808001A GB8808001D0 (en) 1988-04-06 1988-04-06 Stereospecific preparative process for furol(3,4-c)pyridine derivatives

Publications (2)

Publication Number Publication Date
ATA900589A true ATA900589A (de) 1993-06-15
AT397093B AT397093B (de) 1994-01-25

Family

ID=10634633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0900589A AT397093B (de) 1988-04-06 1989-04-06 Stereospezifisches verfahren für die herstellung von enantiomeren des 3-substituierten furo (3,4-c) pyridins, so erhaltene enantiomere oder mischungen davon sowie diese enthaltene therapeutische mittel

Country Status (28)

Country Link
US (1) US5026855A (de)
EP (1) EP0337858B1 (de)
JP (1) JP2680456B2 (de)
KR (1) KR970005308B1 (de)
AT (1) AT397093B (de)
AU (1) AU616753B2 (de)
BE (1) BE1003843A4 (de)
CA (1) CA1338475C (de)
CH (1) CH680000A5 (de)
DK (1) DK167020B1 (de)
DZ (1) DZ1335A1 (de)
ES (1) ES2057159T3 (de)
FI (1) FI93116C (de)
FR (2) FR2629820B1 (de)
GB (2) GB8808001D0 (de)
IE (1) IE61915B1 (de)
IN (1) IN172987B (de)
MA (1) MA21529A1 (de)
MY (1) MY104424A (de)
NL (1) NL8920307A (de)
NZ (1) NZ228614A (de)
OA (1) OA09247A (de)
PT (1) PT90210B (de)
SE (1) SE509130C2 (de)
SG (1) SG40492G (de)
TN (1) TNSN89043A1 (de)
WO (1) WO1989009772A1 (de)
ZA (1) ZA892477B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808001D0 (en) * 1988-04-06 1988-05-05 Scras Stereospecific preparative process for furol(3,4-c)pyridine derivatives
GB8907480D0 (en) * 1989-04-03 1989-05-17 Scaras Societe De Conseils De Separation of insomers of furo(3,4-c)pyridine derivatives
GB8917168D0 (en) * 1989-07-27 1989-09-13 Scras Asymmetric synthesis of furo(3,4-c)pyridine derivatives
US5130252A (en) * 1990-05-14 1992-07-14 Synthetech, Inc. Resolution of furopyridine enantiomers and synthetic precursors thereof
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
WO2008085872A1 (en) * 2007-01-03 2008-07-17 Cornett Glenn V Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
EP2485734B1 (de) 2009-10-09 2014-07-02 Merck Sharp & Dohme Corp. Diuretika
US9522138B2 (en) * 2013-12-31 2016-12-20 Don C. Rockey Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244951A (en) * 1979-05-16 1981-01-13 Pfizer Inc. Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide
IN156817B (de) * 1981-02-10 1985-11-09 Scras
IN160104B (de) * 1983-04-05 1987-06-27 Scras
GB2137618B (en) * 1983-04-05 1986-05-08 Scras Furo-(3,4-c)-pyridine derivatives
ZA842029B (en) * 1983-04-05 1984-10-31 Scras Furo-(3,4-c)-pyridine derivatives preparation thereof and therapeutic compositions containing the same
US4735950A (en) * 1983-04-05 1988-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same
GB8327817D0 (en) * 1983-10-18 1983-11-16 Scras 4-halo-furo-(3 4-c)-pyridine derivatives
GB8330517D0 (en) * 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) * 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
GB8402740D0 (en) * 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
GB8414559D0 (en) * 1984-06-07 1984-07-11 Scras Pyridine derivatives
GB8422029D0 (en) * 1984-08-31 1984-10-03 Scras 6-substituted-furo-(3 4-c)-pyridine derivatives
GB8422379D0 (en) * 1984-09-05 1984-10-10 Scras Derivatives
GB8427218D0 (en) * 1984-10-27 1984-12-05 Scras Pyridine derivatives
DE3519693A1 (de) * 1985-06-01 1987-01-02 Basf Ag Pyridin-derivate, ihre herstellung und verwendung
GB8808001D0 (en) * 1988-04-06 1988-05-05 Scras Stereospecific preparative process for furol(3,4-c)pyridine derivatives
GB8907480D0 (en) * 1989-04-03 1989-05-17 Scaras Societe De Conseils De Separation of insomers of furo(3,4-c)pyridine derivatives

Also Published As

Publication number Publication date
PT90210A (pt) 1989-11-10
WO1989009772A1 (fr) 1989-10-19
FR2629821B1 (fr) 1993-12-03
FR2629820B1 (fr) 1993-12-03
SE8904104L (sv) 1989-12-05
GB2235194A (en) 1991-02-27
DK611689A (da) 1989-12-05
EP0337858A1 (de) 1989-10-18
OA09247A (fr) 1992-06-30
JP2680456B2 (ja) 1997-11-19
NZ228614A (en) 1990-11-27
FI93116B (fi) 1994-11-15
DZ1335A1 (fr) 2004-09-13
IE61915B1 (en) 1994-11-30
GB8927509D0 (en) 1990-06-13
SG40492G (en) 1992-06-12
FI895826A0 (fi) 1989-12-05
IE891076L (en) 1989-10-06
IN172987B (de) 1994-01-15
FR2629821A1 (fr) 1989-10-13
KR900700483A (ko) 1990-08-13
US5026855A (en) 1991-06-25
NL8920307A (nl) 1990-03-01
FR2629820A1 (fr) 1989-10-13
GB8808001D0 (en) 1988-05-05
PT90210B (pt) 1994-06-30
SE509130C2 (sv) 1998-12-07
KR970005308B1 (ko) 1997-04-15
DK167020B1 (da) 1993-08-16
CH680000A5 (de) 1992-05-29
FI93116C (fi) 1995-02-27
BE1003843A4 (fr) 1992-06-30
JPH02504394A (ja) 1990-12-13
MA21529A1 (fr) 1989-12-31
CA1338475C (en) 1996-07-23
ES2057159T3 (es) 1994-10-16
AU3419089A (en) 1989-11-03
AU616753B2 (en) 1991-11-07
EP0337858B1 (de) 1994-06-08
DK611689D0 (da) 1989-12-05
GB2235194B (en) 1992-01-29
TNSN89043A1 (fr) 1991-02-04
ZA892477B (en) 1989-12-27
MY104424A (en) 1994-03-31
AT397093B (de) 1994-01-25
SE8904104D0 (sv) 1989-12-05

Similar Documents

Publication Publication Date Title
AU6760987A (en) Method of treating alzheimer's disease
FI892718A7 (fi) Menetelmä alkoholismin hoidossa käytettävien farmaseuttisten koostumusten valmistamiseksi
DE3885946D1 (de) Kompositstrukturen und Verfahren zum Herstellen derselben.
IT1236831B (it) Apparecchio per il trattamento dell'intestino in particolare per enteroclisma
DE69033509D1 (de) Laserverfahren zur Behandlung von Mikrokapseln oder Teilchen
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE3856398D1 (de) Verfahren zur Behandlung von Gleitkörpern
DE3884973D1 (de) Verfahren zur Herstellung von Avermectine-B und die verwendeten Kulturen.
EP0240307A3 (en) Bipolar transistor and method of producing the same
DE59007596D1 (de) Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Packungen.
DE68916036D1 (de) Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
DE3669328D1 (de) Verfahren und anlage zur serienmaessigen, verzugsarmen thermomechanischen behandlung von werkstuecken sowie anwendung des verfahrens.
ATA900589A (de) Stereospezifisches verfahren fuer die herstellung von enantiomeren des 3-substituierten furo (3,4-c) pyridins, so erhaltene enantiomere oder mischungen davon sowie diese enthaltene therapeutische mittel
EG18730A (en) Substituted tetralin, chromans and related compounds in the treatment of asthma, arthritis and related diseases
DE3883408D1 (de) Verfahren zur Herstellung von Avermectinen und die verwendeten Kulturen.
DE69011951D1 (de) Verfahren zur Behandlung und Herstellung von Material.
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
AU6857887A (en) Therapeutic agent
EP0275668A3 (en) Use of ketone derivatives in the treatment of cognitive disorders
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE58905246D1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
ZA88723B (en) Enantiomers of absolute configuration s of amide derivatives of 3-aminoquinuclidine,the process for preparing them and their application in therapy
DE3675271D1 (de) 1,4-dihydropyridinderivate verwendbar in der behandlung von kardiovaskulaeren stoerungen und verfahren zu ihrer herstellung.
ATA342987A (de) Verschleissteil und verfahren zu seiner herstellung
DE3883072D1 (de) Verfahren und herstellung von olefin-maleinsaeureanhydrid-copolymerteilchen.

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee